#China #Beijing #RNA Therapies #Tsingke Biotech #Nucleic Acid

Tsingke Biotech's 2025 Roundtable on Small Nucleic Acid Therapeutics

On July 26, 2025, Tsingke Biotech, known for its innovations in synthetic biology and nucleic acid solutions, hosted the 2025 Small Nucleic Acid Therapeutics Roundtable in Beijing. The event drew over 100 distinguished scientists, executives from the biotech industry, and research decision-makers who convened to explore the latest advancements in the field of oligonucleotide drug development.

A Gathering of Experts

The roundtable served as a platform for insightful discussions on critical topics surrounding the synthesis, delivery technologies, and commercialization of oligonucleotide therapeutics. Tsingke Biotech showcased its commitment to enhancing the innovation-to-industrialization pipeline with tailored synthesis and platform capabilities.

The event featured a series of keynote speeches and a dynamic panel discussion focusing on the opportunities and challenges currently facing RNA-based therapeutics. Topics deliberated included non-hepatic targeting strategies, the importance of aptamer screening, compliance with chemistry, manufacturing, and controls (CMC), strategies for intellectual property (IP), and next-generation delivery platforms.

Key Highlights from the Roundtable

1. Structural Innovations in Delivery Systems

Experts presented their findings on recent advances in nucleic acid design, particularly highlighting the development of circular and condensed structures that improve both stability and tissue distribution. These innovations promise to enhance the effectiveness of nucleic acid delivery.

2. Targeting Beyond the Liver

Recent innovations introduced new delivery strategies utilizing glycosylated carriers and ring-shaped condensation mechanisms. These methods have shown potential in overcoming significant biological barriers, including the blood-brain barrier, thus expanding the reach of therapeutics into previously inaccessible areas.

3. Advancements in Aptamer Drug Development

Participants engaged in discussions about improved screening techniques that combine solid-liquid interface selection with fluorescence-based validation, fostering the identification of high-affinity aptamer candidates. This reflects the necessity of efficient methodologies in the evolving landscape of drug development.

4. Panel Discussion Insights

Leading industry voices addressed pressing challenges, including:

• - The current gaps in delivery platform technology and core patents within China.
• - The vital role of early-stage CMC planning and the construction of robust platforms.
• - Navigating barriers related to costs, clinical acceptance, and IP risks in the domestic ecosystem.
• - The expected future influence of enzymatic synthesis and cell-free production methods.

Tsingke's Commitment to Innovation

As a driving force behind the roundtable, Tsingke Biotech emphasized its latest advancements in high-purity oligonucleotide synthesis, chemical modification, and raw material support. With a focus on facilitating swifter and more reliable transitions from laboratory solutions to clinical applications, Tsingke is dedicated to advancing RNA therapeutic capabilities across the globe. A spokesperson highlighted the significance of the next decade in shaping the role of oligonucleotides in precision medicine, reinforcing Tsingke's position as a connector between innovation and real-world therapeutic applications.

Conclusion

In conclusion, the 2025 Small Nucleic Acid Therapeutics Roundtable not only underscored current advancements in the field but also set the stage for future collaborations aimed at enhancing the landscape of RNA-based therapeutics. Tsingke Biotech's ongoing commitment to supporting therapeutic developers ensures that significant strides will continue to be made in the realm of nucleic acid solutions. For more information on their nucleic acid synthesis services, visit Tsingke Biotech.